Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy

Stel'makh V.V.

Severo-Zapadnyĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.I. Mechnikova

Kozlov V.K.

Chair of Clinical and Laboratory diagnostics of I.I. Mechnikov Northwest State Medical University, Health Ministry of Russia, Moscow;
Chair of Maxillofacial Surgery and Surgical Dentistry of Saint-Petersburg State University;
Chair of Microbiology, Immunology and Infectious Diseases of Yaroslav Mudryi Novgorod State University, Velikiy Novgorod

Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy

Authors:

Stel'makh V.V., Kozlov V.K.

More about the authors

Journal: Therapeutic Archive. 2013;85(4): 71‑76

Downloaded: 49

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Stel'makh VV, Kozlov VK. Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy. Therapeutic Archive. 2013;85(4):71‑76. (In Russ.)

Close metadata

Recommended articles:

Peculiarities of the nutrition-related health risks formation in persons adhering to traditional and vegetarian diets. Russian Journal of Preventive Medicine. 2024;(4):38-44

Cerebral hemodynamic disorders in patients with schizophrenia with concomitant metabolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):80-85

Predictors of effective complex physiotherapy in patients with skin involution. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(1):13-20

Serum uric acid — a metabolic marker of non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):36-42

Assessment of the condition of organs and tissues of the oral cavity in people with dentition defects against the background of metabolic syndrome. Stomatology. 2024;(3):31-38

A personalized application of therapeutic physical factors in patients with metabolic syndrome. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(2):5-11

Skin alterations as possible clinical markers of diabetes mellitus and metabolic syndrome. Russian Journal of Preventive Medicine. 2024;(7):101-107

Cognitive impairments and emotional disorders and their correction in perimenopausal women. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):48-53

Forensic characteristic of sudden death cases in subjects with metabolic syndrome. Forensic Medical Expertise. 2024;(4):54-57

Metabolic syndrome in clinical psychiatric practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):13-20

Aim. To study the impact of infusion therapy with the metabolic modulator remaxol on lipid metabolic parameters and target organ (liver, kidney) function in metabolic syndrome (MS). Subjects and methods. The investigation enrolled 90 patients (54 men and 36 women) with primary nonalcoholic steatohepatitis that was associated with insulin-resistance and MS; their age was 21 to 77 years. Every day the study group patients (n=50) took as a component of combination therapy the metabolic hepatoprotective modulator remaxol intravenously in a dropwise manner in a dose of 400 ml once daily; the comparison group patients (n=40) received ademetionine 400 mg diluted in 400 ml of isotonic sodium chloride. The duration of infusion therapy was 11 days. Results. Infusion therapy with remaxol caused a pronounced blood lipid composition-regulating effect, by reducing the level of major atherogenic lipids (total cholesterol, triglycerides) and improving liver function and renal nitrogen-excreting and filtration function in patients with Stage IV diabetic nephropathy in the presence of MS. Conclusion. Therapy with the metabolic hepatoprotective modulator remaxol ensures reliable metabolic control and multifactorial correction of risk factors of organ lesions in MS: cardio-, hepato-, and nephroprotection.

Keywords:

nonalcoholic steatohepatitis

metabolic syndrome

dyslipidemia

diabetic nephropathy

remaxol

succinic acid

pathogenetic therapy

Authors:

Stel'makh V.V.

Severo-Zapadnyĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.I. Mechnikova

Kozlov V.K.

List of references:

Belentani S., Scaglioni F., Marino M. et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-161.
Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
Guzman G., Brunt E.M., Petrovic L.M. et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008; 132: 1761-1766.
Caldwell S., Argo C. The natural history of nonalcoholic fatty liver disease. Dig Dis 2010; 28: 162-168.
Marchesini G., Bugianesi E., Forlani G. et al. Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology 2003; 37: 917-923.
Belentani S., Marino M. Epidemiology and natural history of nonalcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8 (suppl. 1): S4-S8.
Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in nonalcoholic fatty liver disease. J Hepatol 2008; 49: 608-612.
Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000; 21 (3): 49-98.
Bueverov A.O. Zhirnaya pechen': prichiny i posledstviya. Praktikuyushchii vrach 2002; 1: 36-38.
Fraze E., Donner C.C., Swislocki A.L. et al. Ambient plasma free fatty acid concentration in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrin Metab 1985; 61 (5): 807-811.
Balabolkin M.I. Diabetologiya. M: Meditsina 2000.
Mamedov M.N. Osobennosti lipidnykh narushenii u bol'nykh sakharnym diabetom 2-go tipa: v kakikh sluchayakh sleduet primenyat' statiny? Kardiologiya 2006; 3: 90-95.
Kostin V.I., Karpov V.S. Kachestvo zhizni patsientov s kardial'nym sindromom Kh. Klin med 2001; 1: 25-27.
Sholesterol Treatment Trialists (CTT) Colaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
Reiner Z., Catapano A.L., De Backer G. et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the Europpean Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32 (14): 1769-1818.
Stel'makh V.V., Kozlov V.K., Radchenko V.G., Nekrasova A.S. Patogeneticheskaya terapiya metabolicheskogo sindroma na stadii organnykh porazhenii. Klin med 2012; 7: 35-41.
Sologub T.V., Goryacheva L.G., Sukhanov D.S. i dr. Gepatoprotektivnaya aktivnost' remaksola pri khronicheskikh porazheniyakh pecheni. Klin med 2010; 1: 1-4.

Close metadata